GLP-1 Receptor Agonists and Diverticular Disease Risk
GLP-1 receptor agonists do not increase the risk of diverticular disease (diverticulosis or diverticulitis) in adults with type 2 diabetes. The available evidence shows no association between GLP-1 RA therapy and diverticular complications, though these medications do carry a moderate risk of other gastrointestinal adverse events that warrant consideration.
Evidence on Diverticular Disease Risk
The most comprehensive recent safety data on GLP-1 RAs demonstrates no increased risk of intestinal obstruction or diverticular-related complications:
A 2025 large-scale retrospective cohort study of over 1.2 million patients with type 2 diabetes found no increased risk of intestinal obstruction with GLP-1 RAs compared to other anti-diabetic medications (except for a reduced risk compared to insulins), with consistent findings across 1,3, and 5-year follow-up periods 1.
A 2025 meta-analysis of 55 randomized controlled trials involving 106,395 participants found that GLP-1 RAs probably have little or no effect on the risk of intestinal obstruction, paralytic ileus, or gastrointestinal perforation 2.
The 2025 real-world cohort study of 230,415 matched patients per group showed no significant differences in most serious gastrointestinal outcomes, though it did identify increased risks for gastroparesis and intussusception 3.
Actual Gastrointestinal Risks to Consider
While diverticular disease is not a concern, GLP-1 RAs do carry documented gastrointestinal risks that require clinical attention:
Established increased risks (moderate certainty evidence):
- Severe gastrointestinal events are recognized as a harm across risk categories in the 2025 BMJ guidelines 4.
- Cholelithiasis risk increases by 46% (RR 1.46; 95% CI 1.09-1.97), translating to 2 additional cases per 1000 patients 2.
- Gastroesophageal reflux disease (GERD) risk more than doubles (RR 2.19; 95% CI 1.48-3.25), with 4 additional cases per 1000 patients 2.
- Gastroparesis shows increased incidence (HR 1.591, P < 0.001) 3.
These risks are more pronounced in:
- Patients with overweight/obesity or metabolic dysfunction-associated steatotic liver disease 2
- Those receiving high-dose formulations 2
- Individuals with preexisting GI motility disorders 5
Clinical Decision-Making Framework
For patients at moderate to high cardiovascular/kidney risk:
- The cumulative cardiovascular and kidney benefits (moderate to high certainty evidence) outweigh gastrointestinal risks 4.
- Use GLP-1 RAs when indicated for cardiovascular or kidney protection, as diverticular disease is not a contraindication 6, 4.
For patients at lower cardiovascular/kidney risk:
- Given little cardiovascular benefit but persistent gastrointestinal risks, most patients would be disinclined to accept GLP-1 RAs 4.
- The exception is patients with obesity seeking weight reduction, who may value this benefit despite GI risks 4.
Key Clinical Caveats
Avoid cumulative gastrointestinal burden:
- Patients already taking medications with GI side effects (such as metformin) may choose to avoid GLP-1 RAs if the cumulative risk of gastrointestinal events exceeds anticipated benefits 4.
Monitor for gastroparesis and delayed gastric emptying:
- The slowing of gastric emptying increases propensity for retained gastric contents, potentially raising aspiration risk during upper GI endoscopy or general anesthesia 7.
- These risks require vigilance in susceptible individuals 3.
History of GI motility disorders:
- Exercise caution in patients with prior small bowel obstruction or known motility issues, as GLP-1 RAs reduce gut motility by slowing gastric emptying and altering the migrating motor complex 5.
Type 2 Diabetes and Diverticular Disease Context
Importantly, type 2 diabetes itself appears associated with a slightly lower risk of diverticular disease after adjustment for BMI (adjusted HR 0.88; 95% CI 0.80-0.96), with even lower risk among those with ≥5 years diabetes duration (adjusted HR 0.76; 95% CI 0.67-0.87) 8. This further supports that GLP-1 RA therapy in diabetic patients does not pose diverticular disease concerns.